Literature DB >> 8381633

A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex.

C J Willmott1, A Maxwell.   

Abstract

Binding of the quinolone drug norfloxacin to gyrase and DNA has been investigated. We have detected binding to gyrase-DNA complex but find no significant binding to either gyrase or DNA alone. Enzyme containing gyrase A protein with the mutation Ser-83 to Trp (conferring quinolone resistance) showed greatly reduced drug binding.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8381633      PMCID： PMC187618          DOI： 10.1128/AAC.37.1.126

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  The molecular basis of quinolone action.

Authors:  A Maxwell
Journal:  J Antimicrob Chemother       Date:  1992-10       Impact factor: 5.790

2.  Cloning of the DNA gyrase genes under tac promoter control: overproduction of the gyrase A and B proteins.

Authors:  P Hallett; A J Grimshaw; D B Wigley; A Maxwell
Journal:  Gene       Date:  1990-09-01       Impact factor: 3.688

3.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.

Authors:  L L Shen; L A Mitscher; P N Sharma; T J O'Donnell; D W Chu; C S Cooper; T Rosen; A G Pernet
Journal:  Biochemistry       Date:  1989-05-02       Impact factor: 3.162

4.  Tryptic fragments of the Escherichia coli DNA gyrase A protein.

Authors:  R J Reece; A Maxwell
Journal:  J Biol Chem       Date:  1989-11-25       Impact factor: 5.157

5.  Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes.

Authors:  L L Shen; W E Kohlbrenner; D Weigl; J Baranowski
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

6.  The DNA dependence of the ATPase activity of DNA gyrase.

Authors:  A Maxwell; M Gellert
Journal:  J Biol Chem       Date:  1984-12-10       Impact factor: 5.157

7.  Site-specific interaction of DNA gyrase with DNA.

Authors:  L M Fisher; K Mizuuchi; M H O'Dea; H Ohmori; M Gellert
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

8.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

9.  Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins.

Authors:  P Hallett; A Maxwell
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

10.  Quinolone-resistant mutations of the gyrA gene of Escherichia coli.

Authors:  H Yoshida; T Kojima; J Yamagishi; S Nakamura
Journal:  Mol Gen Genet       Date:  1988-01
View more
  84 in total

1.  New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Authors:  C Janoir; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Inhibition of Escherichia coli viability by external guide sequences complementary to two essential genes.

Authors:  J McKinney; C Guerrier-Takada; D Wesolowski; S Altman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

3.  Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Pengfei Wang; Robert J Kerns; David E Graves; Charles L Turnbough; Neil Osheroff
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

4.  parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.

Authors:  Kendal M Galbraith; Amanda C Ng; Betsy J Eggers; Craig R Kuchel; Christian H Eggers; D Scott Samuels
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Authors:  Alexandra Aubry; Nicolas Veziris; Emmanuelle Cambau; Chantal Truffot-Pernot; Vincent Jarlier; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.

Authors:  Jacob Strahilevitz; Ari Robicsek; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

7.  Limited effects of temafloxacin compared with ciprofloxacin on T-lymphocyte function.

Authors:  K Riesbeck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 9.  Quinolone mode of action--new aspects.

Authors:  D C Hooper
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.